IVIG and rituximab for treatment of chronic antibody-mediated rejection: A prospective study in paediatric renal transplantation with a 2-year follow-up

Transplant International

Volumn 25, Issue 11, 2012, Pages 1165-1173

  Billing, Heiko ^a   Rieger, Susanne ^a   Süsal, Caner ^b   Waldherr, Rüdiger ^c   Opelz, Gerhard ^b   Wühl, Elke ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute for Clinical Pathology   (Germany)

Author keywords

chronic antibody mediated rejection; donor specific HLA antibodies; IVIG; paediatric renal transplantation; rituximab

Indexed keywords

CREATININE; CYCLOSPORIN A; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; PEDIATRIC SURGERY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; TRANSPLANT GLOMERULOPATHY;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TISSUE DONORS; YOUNG ADULT;

EID: 84867517639     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01544.x     Document Type: Article

References (35)

1. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
2. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
3. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
4. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
5. Bartel G, Schwaiger E, Böhmig GA,. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142.
6. Fehr T, Gaspert A,. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623.
7. Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
8. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006; 6: 1790.
9. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
10. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am Transplant 2006; 6: 1841.
11. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
12. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826.
13. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
14. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214.
15. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
16. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629.
17. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tönshoff B,. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006; 28: 623.
18. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
19. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058.
20. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758.
21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
22. Cosio FG, Gloor JM, Sethi S, Stegall MD,. Transplant glomerulopathy. Am J Transplant 2008; 8: 492.
23. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
24. Jordan SC, Toyoda M, Vo AA,. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7: 341.
25. Salama AD, Pusey CD,. Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 2: 221.
26. Steinmetz OM, Lange-Hüsken F, Turner JE, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842.
27. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
28. Jordan SC, Kahwaji J, Toyoda M, Vo A,. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011; 16: 416.
29. Fehr T, Rüsi B, Fischer A, et al. Rituximab and intra-venous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837.
30. Clatworthy MR,. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359.
31. Wahrmann M, Haidinger M, Körmöczi GF, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385.
32. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
33. Lubetzky M, Auli MJ, Walker J, et al. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection. Clin Transpl 2010; 437.
34. Schwaiger E, Regele H, Wahrmann M, et al. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Clin Transpl 2010; 391.
35. Vogelbacher R, Meister S, Gückel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010; 25: 3764.